Literature DB >> 8090382

Neonatal group B streptococcal sepsis during 2 years of a universal screening program.

R S Gibbs1, R S McDuffie, F McNabb, G E Fryer, T Miyoshi, G Merenstein.   

Abstract

OBJECTIVE: To assess the feasibility and efficacy of a protocol for universal screening for group B streptococci combined with selective intrapartum prophylaxis at a teaching hospital.
METHODS: This is a descriptive study of experience with a standardized protocol in which patients were screened at 26-28 weeks with a rectal and genital culture placed directly in selective media. As risk factors, we used clinical chorioamnionitis, preterm birth, and rupture of the membranes greater than 12 hours. Participants were all women receiving prenatal care at our hospital. Major outcomes were compliance and neonatal sepsis due to group B streptococci.
RESULTS: The prevalence of rectal and genital group B streptococci was 18.5% of 3721 screened women. Of culture-positive women, 35% developed risk factors (9% chorioamnionitis, 13% preterm birth, and 13% membrane rupture greater than 12 hours at term). With strict application of criteria, the compliance rate in administering indicated prophylaxis was 80.3%. Of women receiving prophylaxis, 42% had the first dose for 4 hours or less before delivery. There were five cases of group B streptococcal neonatal sepsis, resulting from either protocol violations, protocol failures, or both. Compared to the historic rate of group B streptococcal sepsis of 1.5 per 1000 births at our hospital, the rate in these 2 years was 1.0 per 1000 (1.6 per 1000 in the first year and 0.5 per 1000 in the second).
CONCLUSIONS: It is feasible to conduct such a protocol, but compliance is only moderately good because the algorithm is complex. The protocol is not foolproof in preventing neonatal group B streptococcal sepsis, as there are protocol failures and violations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8090382

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  11 in total

1.  Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Prevention of group B streptococcal infection in newborns. Recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors: 
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

3.  Rapid detection of group B streptococcal colonization of the genital tract by a commercial optical immunoassay.

Authors:  K C Carroll; D Ballou; M Varner; H Chun; R Traver; J Salyer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

4.  The Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of neonatal group B streptococcal infections in Canada.

Authors:  H D Davies; J Leblanc; R Bortolussi; A McGeer
Journal:  Paediatr Child Health       Date:  1999-05       Impact factor: 2.253

5.  Screening pregnant women for group B streptococcal colonization.

Authors:  T A Madani; G K Harding; M Helewa; M J Alfa
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

Review 6.  Epidemiology of group B streptococcal disease in the United States: shifting paradigms.

Authors:  A Schuchat
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

7.  Compliance with a protocol for intrapartum antibiotic prophylaxis against neonatal group B streptococcal sepsis in women with clinical risk factors.

Authors:  Toni R Sanders; Christine L Roberts; Gwendolyn L Gilbert
Journal:  Infect Dis Obstet Gynecol       Date:  2002

8.  Compliance with protocols for prevention of neonatal group B streptococcal sepsis: practicalities and limitations.

Authors:  Gwendolyn L Gilbert; Moira C Hewitt; Catherine M Turner; Stephen R Leeder
Journal:  Infect Dis Obstet Gynecol       Date:  2003

9.  Randomized clinical trial of intrapartum clindamycin cream for reduction of group B streptococcal maternal and neonatal colonization.

Authors:  R S Gibbs; F McNabb
Journal:  Infect Dis Obstet Gynecol       Date:  1996

10.  Compliance with a risk-factor-based guideline for the prevention of neonatal group B streptococcal sepsis.

Authors:  M T Fleming; R S McDuffie; K Russell; S Meikle
Journal:  Infect Dis Obstet Gynecol       Date:  1997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.